Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide combined with dexamethasone for refractory or recurrent bone Langerhans cell histiocytosis after failed prior chemotherapy/hormone therapy
ChiCTR1900021579Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide and dexamethasone in Langerhans cell histiocytosis (LCH), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
lenalidomidedexamethasone
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR1900021579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021579.